Question-and-Answer Session
Operator
(Operator Instructions) We will take our first question from David Buck with Buckingham Research.
David Buck - Buckingham Research
Hi, yes. Thanks for taking my question. Just three quick questions. First for Frank or Kevin, what precipitated the reserve and the timing of the reserve for the investigations? Secondly, for either Frank or Bob Roche, on the Takeda co-promo, can you give an update how you are tracking productivity of that and we really haven't seen at least from our expectation, some of the prescription growth we had expected from primary care and if you could talk about when you see that happening? And for FENTORA, should we be assuming a similar growth rate absent, any new indications? I mean, basically, just some incremental sequential growth for that product. Thanks.
Frank Baldino
Thanks David. I think regarding the timing of this, I think it's just straight to say, we recorded this reserve, as we know it's appropriate to do so. The most important thing about this reserve is what Kevin said in his comments that you should look at this as nothing more than the reserve that we put on the books, and that the final outcome will likely be materially larger than this. I think that's enough said about that. Bob, do you want to answer David's question on both FENTORA and PROVIGIL?
Bob Roche
Yes, sure. David, good afternoon. Yes, with regard to PROVIGIL first, David, I think we remained very positive on the effects of Takeda is both offering now and will continue to offer as we go through the end of the year. We are embarking on a number of pretty exciting new initiatives with PROVIGIL and these are ones which we are working very closely on with Takeda and expect will continue to really energize this partnership and drive even better results.
And Frank mentioned in his opening remarks, our new initiatives in obstructive sleep apnea and the exciting new data which has come out just recently that not only demonstrates how tired these people continue to be even after a good solid usage of their [C-Path] devices but also other data that demonstrate the really high levels of co morbidities with these disease that many of which I think exacerbate these issues of sleepiness and tiredness of these people feel thing such as diabetes, obesity, depression and cardiovascular disorder, so we are very excited about the opportunities in OSA and have just recently as a matter of fact trained our sales force on a whole variety of new messaging and new promotional techniques for this particular market. And Takeda is following that lead.
- To read the full transcript on Seeking Alpha, click here »
